Koji Tamada

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 7

Top Topics

Renal Cell Carcinoma

Tyrosine Kinase

Top Venues

Cancer immunology, immunotherapy : CII

Cancer research communications

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Keisuke Ohta, Yukimi Sakoda, Keishi Adachi, Taro Shinozaki, Masao Nakajima, Hiroyuki Yasuda, Hiroaki Nagano, Koji Tamada
Therapeutic efficacy of IL-7/CCL19-expressing CAR-T cells in intractable solid tumor models of glioblastoma and pancreatic cancer. Cancer research communications (2024)
Toshiki Anami, Cheng Pan, Yukio Fujiwara, Yoshihiro Komohara, Hiromu Yano, Yoichi Saito, Masamichi Sugimoto, Daiko Wakita, Takanobu Motoshima, Yoji Murakami, Junji Yatsuda, Naofumi Takahashi, Shinya Suzu, Kenichi Asano, Koji Tamada, Tomomi Kamba
Dysfunction of sinus macrophages in tumor-bearing host induces resistance to immunotherapy. Cancer science (2023)
Takahiro Sasaki, Yukimi Sakoda, Keishi Adachi, Yoshihiro Tokunaga, Koji Tamada
Therapeutic effects of anti-GM2 CAR-T cells expressing IL-7 and CCL19 for GM2-positive solid cancer in xenograft model. Cancer medicine (2023)
Keishi Adachi, Koji Tamada
Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors. Cancer science (2022)
Jun-Ich Mori, Keishi Adachi, Yukimi Sakoda, Takahiro Sasaki, Shunsuke Goto, Hiroaki Matsumoto, Yoji Nagashima, Hideyasu Matsuyama, Koji Tamada
Anti-tumor efficacy of human anti-c-met CAR-T cells against papillary renal cell carcinoma in an orthotopic model. Cancer science 112 (4) (2021)
Shunsuke Goto, Yukimi Sakoda, Keishi Adachi, Yoshitaka Sekido, Seiji Yano, Masatoshi Eto, Koji Tamada
Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models. Cancer immunology, immunotherapy : CII 70 (9) (2021)
Masao Nakajima, Yukimi Sakoda, Keishi Adachi, Hiroaki Nagano, Koji Tamada
Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells. Cancer science 110 (10) (2019)